Prenatal overexposure to glucocorticoids programs renal 11β-hydroxysteroid dehydrogenase type 2 expression and salt-sensitive hypertension in the rat

被引:35
|
作者
Tang, Justin I. [1 ]
Kenyon, Chris J. [1 ]
Seckl, Jonathan R. [1 ]
Nyirenda, Moffat J. [1 ]
机构
[1] Univ Edinburgh, Ctr Cardiovasc Sci, Queens Med Res Inst, Endocrinol Unit, Edinburgh EH16 4TJ, Midlothian, Scotland
关键词
11 beta-hydroxysteroid dehydrogenase type 2; fetal programming; glucocorticoids; hypertension; salt sensitivity; APPARENT MINERALOCORTICOID EXCESS; CORTISOL-CORTISONE SHUTTLE; BLOOD-PRESSURE; MOLECULAR MECHANISMS; ADULT DISEASE; RECEPTOR; GROWTH; EXPOSURE; LICORICE; FETAL;
D O I
10.1097/HJH.0b013e328340aa18
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective Prenatal glucocorticoid excess programs hypertension in adulthood. The underlying mechanisms are unknown. Here, we tested whether hypertension in this model is due to increased renal mineralocorticoid activity. Methods Pregnant rats were injected daily with the synthetic glucocorticoid dexamethasone (DEX) or vehicle during the last week of pregnancy. Blood pressure, electrolytes and target gene expression were measured in the offspring. Results Adult DEX-treated offspring were hypertensive (SBP, 140.1 +/- 2.4 vs. 128.6 +/- 3.2 mmHg; P=0.009), hypokalemic (4.5 +/- 0.2 vs. 5.1 +/- 0.2 mmol/l; P=0.03) and had suppressed plasma renin concentration (23.6 +/- 4.8 vs. 43.8 +/- 5.9 ng/ml; P=0.017). DEX programming had similar effects in younger rats (age 2 months), but only when fed a high-salt diet. Although these data are consistent with excess mineralocorticoid activity, plasma aldosterone levels were unaffected and daily urinary aldosterone values were decreased (136.1 +/- 27.0 vs. 303.6 +/- 47.0 ng/kg; P=0.008). Accordingly, we assessed renal factors that might influence mineralocorticoid responsiveness. Renal expression of mineralocorticoid receptor and glucocorticoid receptor mRNAs was unaltered, as was 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) which regenerates active glucocorticoids. However, renal mRNA for 11 beta-HSD2, which catalyses inactivation of glucocorticoids in the distal nephron and thus protects mineralocorticoids from glucocorticoids, was decreased by 45% in both new born and adult rats (P<0.01). The functional significance of this reduction was confirmed by measurements of renal 11 beta-HSD activity and by demonstrating that the mineralocorticoid properties of cortisol were enhanced in DEX-programmed rats. Additionally, the difference in blood pressure between DEX and control groups was abolished upon administration of spironolactone, a mineralocorticoid receptor antagonist. Conclusion The blood pressure phenotype of DEX-programmed rats may in part be explained by a life-long reduction in renal 11 beta-HSD2 activity. Salt-sensitive hypertension could be programmed by prenatal stress. J Hypertens 29:282-289 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:282 / 289
页数:8
相关论文
共 50 条
  • [41] Cloning and expression of the bovine 11β-hydroxysteroid dehydrogenase type-2
    Romero, DG
    Zhou, MY
    Gomez-Sanchez, CE
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 72 (05): : 231 - 237
  • [42] Expression of 11β-hydroxysteroid dehydrogenase type 2 is deregulated in colon carcinoma
    Moravec, Martin
    Svec, Jiri
    Ergang, Peter
    Mandys, Vaclav
    Rehakova, Lenka
    Zadorova, Zdena
    Hajer, Jan
    Kment, Milan
    Pacha, Jiri
    HISTOLOGY AND HISTOPATHOLOGY, 2014, 29 (04) : 489 - 496
  • [43] Increased renal expression of aquaporin-3 in rats inhibited type 2 11β-hydroxysteroid dehydrogenase
    Ma, Seong Kwon
    Nam, Kwang Il
    Kim, Soo Wan
    Bae, Eun Hui
    Choi, Ki Chul
    Lee, JongUn
    KIDNEY & BLOOD PRESSURE RESEARCH, 2007, 30 (01): : 8 - 14
  • [44] 11β-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis
    Kosicka, K.
    Cymerys, M.
    Majchrzak-Celinska, A.
    Chuchracki, M.
    Glowka, F. K.
    JOURNAL OF HUMAN HYPERTENSION, 2013, 27 (08) : 510 - 515
  • [45] 11β-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis
    K Kosicka
    M Cymerys
    A Majchrzak-Celińska
    M Chuchracki
    F K Główka
    Journal of Human Hypertension, 2013, 27 : 510 - 515
  • [46] Organotins disrupt the 11β-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids
    Atanasov, AG
    Nashev, LG
    Tam, S
    Baker, ME
    Odermatt, A
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2005, 113 (11) : 1600 - 1606
  • [47] 11β-Hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids
    Holmes, MC
    Sangra, M
    French, KL
    Whittle, IR
    Paterson, J
    Mullins, JJ
    Seckl, JR
    NEUROSCIENCE, 2006, 137 (03) : 865 - 873
  • [48] Inactivation of glucocorticoids in osteoblasts by targeted overexpression of 11β-hydroxysteroid dehydrogenase type 2 in transgenic mice
    Woitge, HW
    Kalajzic, I
    Clark, SH
    Gronowicz, G
    Krozowski, Z
    Harrison, JR
    Kream, BE
    BONE, 2001, 28 (05) : S75 - S75
  • [49] EXPRESSIONAL AND FUNCTIONAL CHANGES OF PLACENTAL 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 2 CAUSED BY SYNTHETIC GLUCOCORTICOIDS
    Vackova, Zuzana
    Mazancova, Karla
    Libra, Antonin
    Miksik, Ivan
    Pacha, Jiri
    Staud, Frantisek
    DRUG METABOLISM REVIEWS, 2007, 39 : 129 - 130
  • [50] Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension
    Hermann, M
    Shaw, S
    Luscher, TF
    Grone, HJ
    Ruschitzka, F
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 129A - 129A